ABOS
$2.67
+$0.07 (2.75%)+2.75%
ClosedLoading chart...
IndexN/A
Market Cap0.19B
Enterprise Value0.11B
Income$-0.03B
Sales$0.00B
EmployeesN/A
P/E-1.44
P/S0.00
P/B1.81
P/C-1.11
EV/EBITDA-0.90
EV/SalesN/A
EPS (ttm)-1.86
EarningsN/A
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Volume0.52M
Shs Outstand0.07B
Change4.71%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.44M | $1.70M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $12.30M | $8.00M | $8.58M |
| Gross Profit | $0.00 | $0.00 | $0.00 | $-12.30M | $-6.56M | $-6.88M |
| Gross Margin | N/A | N/A | N/A | N/A | -456.89% | -405.36% |
| Operating Expenses | $114.02M | $61.14M | $45.24M | $7.28M | $1.35M | $926.00K |
| Operating Income | $-114.02M | $-61.14M | $-45.24M | $-19.58M | $-7.91M | $-7.80M |
| Operating Margin | N/A | N/A | N/A | N/A | -550.97% | -459.93% |
| Net Income | $-102.33M | $-52.37M | $-42.86M | $-100.61M | $-7.33M | $-7.91M |
| Net Margin | N/A | N/A | N/A | N/A | -510.10% | -465.94% |
| EPS (Basic) | $-1.71 | $-1.08 | $-1.06 | $-2.63 | $-0.26 | $-0.20 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $238.99M | $310.13M | $196.59M | $230.33M | $44.43M | $7.32M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $57.18M | $43.15M | $7.81M | $5.15M | $63.02M | $18.74M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $181.82M | $266.97M | $188.78M | $225.18M | $-18.59M | $-11.42M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $181.82M | $266.97M | $188.78M | $225.18M | $-18.59M | $-11.42M |
| Total Liabilities & Stockholders Equity | $238.99M | $310.13M | $196.59M | $230.33M | $44.43M | $7.32M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-102.33M | $-52.37M | $-42.86M | $-100.61M | $-7.33M | $-7.91M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-86.22M | $-43.06M | $-35.15M | $-17.96M | $-7.45M | $-6.82M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business HighlightsGlobeNewswire Inc. Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care ConferenceGlobeNewswire Inc. Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026GlobeNewswire Inc. Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026GlobeNewswire Inc. Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS ForumGlobeNewswire Inc. Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025GlobeNewswire Inc. Acumen Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025GlobeNewswire Inc.
Show 12 more stories
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025GlobeNewswire Inc. Acumen Pharmaceuticals to Participate in the Bank of America Healthcare ConferenceGlobeNewswire Inc. Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025GlobeNewswire Inc. Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual MeetingGlobeNewswire Inc. Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR ReportGlobeNewswire Inc. Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual MeetingGlobeNewswire Inc. Acumen Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceGlobeNewswire Inc. Acumen Pharmaceuticals to Participate in the UBS Global Healthcare ConferenceGlobeNewswire Inc. Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceGlobeNewswire Inc. Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024GlobeNewswire Inc. 4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.comInvesting.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Discover more
You may be interested in